The similar and consistently significant results under the additive and codominant genetic inheritance models imply that the clinical benefit for colorectal cancer patients treated with cetuximab could be additive in nature, with an improvement of approximately ~30% in survival benefit for every H allele of FCGR2A. This evidence concerns the gene FCGR2A and colorectal cancer.